MedPath

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

Phase 3
Completed
Conditions
Acne Vulgaris
Interventions
Registration Number
NCT03522441
Lead Sponsor
Akorn, Inc.
Brief Summary

This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel (Greenstone LLC) in the treatment of acne vulgaris.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1125
Inclusion Criteria
  • Male or non-pregnant, non-lactating female, ≥12 and ≤40 years of age with a clinical diagnosis of acne vulgaris.
  • Have facial acne with: ≥20 facial inflammatory lesions (papules and pustules) and ≥25 non-inflammatory lesions (open and closed comedones), and ≤2 nodulocystic lesions (nodules and cysts) and have an IGA score of 2, 3 or 4.
Exclusion Criteria
  • Subject has more than 2 facial nodular lesions; any nodules present will be documented but not included in the inflammatory lesion count for analysis.
  • Subject has active cystic acne.
  • Subject has acne conglobata.
  • Subjects with excessive facial hair such as beards, sideburns, moustaches, etc. that would interfere with the diagnosis or assessment of acne.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Clindamycin 1% gel (Akorn Pharmaceuticals)Clindamycin 1% Gel-
Clindamycin 1% gel (Greenstone LLC)Clindamycin 1% Gel-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Percent Change in the Number of Inflamed Lesions (Papules/Pustules)- Time Frame: Baseline to 12 WeeksPercent change from baseline to 12 weeks
Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Counts - Change in Baseline to 12 WeekPercent change in baseline to 12 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (12)

Site 1

🇺🇸

Brandon, Florida, United States

Site 11

🇺🇸

Encino, California, United States

Site 4

🇺🇸

Miramar, Florida, United States

Site 10

🇺🇸

Sherman Oaks, California, United States

Site 5

🇺🇸

Miramar, Florida, United States

Site 3

🇺🇸

Tampa, Florida, United States

Site 2

🇺🇸

Tampa, Florida, United States

Site 12

🇺🇸

High Point, North Carolina, United States

Site 9

🇺🇸

El Paso, Texas, United States

Site 8

🇺🇸

El Paso, Texas, United States

Site 6

🇧🇿

Belize City, Belize

Site 7

🇧🇿

Belize City, Belize

© Copyright 2025. All Rights Reserved by MedPath